Quantcast

Corvus Pharmaceuticals closer to submitting Investigational New Drug application for CPI-818

Corvus Pharmaceuticals’s study of its investigational small molecule T-cell signaling pathway inhibitorresults, indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity.

Read more

Corvus Pharmaceuticals enrolls patients to test combination of two drugs from its programs

Oncology focused pharmaceutical company Corvus Pharmaceuticals has started enrolling patients in the second arm of its ongoing Phase 1/1b dose-escalation study to test combination of CPI-006, a humanized monoclonal antibody directed against CD73, with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor.

Read more